{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:13:59Z","timestamp":1787015639132,"version":"build-2736575974"},"reference-count":8,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic hepatitis D (CHD) is a severe form of viral hepatitis that leads to liver cirrhosis and hepatocellular carcinoma. CHD is underdiagnosed, and this study aimed to assess the impact of hepatitis D reflex testing in HBsAg\u2010positive individuals in Spain over the next 8\u2009years. Two scenarios were compared: the current situation (7.6% of HBsAg\u2010positive patients tested for anti\u2010HDV) and reflex testing for all positive samples. A decision tree model was designed to simulate the CHD care cascade. Implementing reflex testing would increase anti\u2010HDV detection to 5498 cases and HDV\u2010RNA to 3225 cases. Additionally, 2128 more patients would receive treatment, with 213 achieving undetectable HDV\u2010RNA levels. The cost per anti\u2010HDV case detected would be \u20ac132. In the median time of the analysis, liver complications (decompensated cirrhosis, HCC and liver\u2010related deaths) would be reduced by 35%\u201338%, implying an estimated cost savings of 36 million euros associated with the management of such complications. By 2030, implementing anti\u2010HDV reflex testing would reduce the clinical and economic burden of CHD by 35%\u201338%.<\/jats:p>","DOI":"10.1111\/liv.15776","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T06:59:00Z","timestamp":1698908340000},"page":"2611-2614","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Impact of hepatitis D reflex testing on the future disease burden: A modelling analysis"],"prefix":"10.1111","volume":"43","author":[{"given":"Maria","family":"Buti","sequence":"first","affiliation":[{"name":"Liver Unit Hospital Universitari Vall d'Hebron  Barcelona Spain"},{"name":"CIBERHERD Instituto de Salud Carlos III  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Dom\u00ednguez\u2010Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Pharmacoeconomics &amp; Outcomes Research Iberia (PORIB)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-1302","authenticated-orcid":false,"given":"Adriana","family":"Palom","sequence":"additional","affiliation":[{"name":"Liver Unit Hospital Universitari Vall d'Hebron  Barcelona Spain"},{"name":"CIBERHERD Instituto de Salud Carlos III  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[{"name":"Liver Unit Hospital Universitari Vall d'Hebron  Barcelona Spain"},{"name":"CIBERHERD Instituto de Salud Carlos III  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Casado","sequence":"additional","affiliation":[{"name":"Pharmacoeconomics &amp; Outcomes Research Iberia (PORIB)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100547"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2020.114039"},{"key":"e_1_2_8_5_1","unstructured":"Consejo Interterritorial Sistema Nacional de Salud Ministerio de Sanidad. 2oEstudio Seroprevalencia en Espa\u00f1a.2021Available fromhttps:\/\/www.sanidad.gob.es\/en\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/comoTrabajamos\/docs\/EstudioSeroprevalencia_EnfermedadesInmunoprevenibles.pdf"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13366"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15521"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30663-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0009.8590"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:14:01Z","timestamp":1704291241000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.15776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":8,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/liv.15776"],"URL":"https:\/\/doi.org\/10.1111\/liv.15776","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"2023-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}